Carrier‐free nanodrugs composed of photosensitizer Verteporfin and mammalian target of rapamycin inhibitor Torin 1 are designed for breast cancer treatment with improved photodynamic therapy and tumor microenvironment reshaping effects. The gene discussed is MTOR; the disease is breast cancer.